A Phase I/II Trial of ABI-008 (nab-docetaxel) in Patients with Metastatic Breast Cancer

Trial Profile

A Phase I/II Trial of ABI-008 (nab-docetaxel) in Patients with Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2009

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abraxis BioScience
  • Most Recent Events

    • 11 Jun 2009 Last checked against ClinicalTrials.gov record.
    • 06 Nov 2008 Status changed from active, no longer recruiting to discontinued, based on information from ClinicalTrials.gov.
    • 10 Mar 2008 The expected completion date for this trial is now 1 Dec 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top